Tools
ToolsReynolds, Catherine J., Pade, Corinna, Gibbons, Joseph M., Otter, Ashley D., Lin, Kai-Min, Sandoval, Diana Muñoz, Pieper, Franziska P., Butler, David K., Liu, Siyi, Joy, George, Forooghi, Nasim, Treibel, Thomas A., Manisty, Charlotte, Moon, James C., Semper, Amanda, Brooks, Tim, McKnight, Áine, Altmann, Daniel M. and Boyton, Rosemary J. and COVIDsortium Investigators, COVIDsortium Immune Correlates Network (2022) Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science, 377 (6603). ISSN 0036-8075
Preview |
PDF (Reynolds_etal_2022_Science)
- Published Version
Available under License Creative Commons Attribution. Download (2MB) | Preview |
Abstract
The Omicron, or Pango lineage B.1.1.529, variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and partial neutralizing antibody (nAb) escape. Vaccinated individuals show protection against severe disease, often attributed to primed cellular immunity. We investigated T and B cell immunity against B.1.1.529 in triple BioNTech BNT162b2 messenger RNA-vaccinated health care workers (HCWs) with different SARS-CoV-2 infection histories. B and T cell immunity against previous variants of concern was enhanced in triple-vaccinated individuals, but the magnitude of T and B cell responses against B.1.1.529 spike protein was reduced. Immune imprinting by infection with the earlier B.1.1.7 (Alpha) variant resulted in less durable binding antibody against B.1.1.529. Previously infection-naïve HCWs who became infected during the B.1.1.529 wave showed enhanced immunity against earlier variants but reduced nAb potency and T cell responses against B.1.1.529 itself. Previous Wuhan Hu-1 infection abrogated T cell recognition and any enhanced cross-reactive neutralizing immunity on infection with B.1.1.529.
| Item Type: | Article |
|---|---|
| Additional Information: | Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper or the supplementary materials. The SARS-CoV-2 Wuhan Hu-1 Human 2019-nCoV, B.1.351, P.1, B.1.617.2, and B.1.1.529 isolates were obtained under material agreements with EVAg, France. The SARS-CoV-2 B.1.1.7 isolate was obtained under a material agreement with NIBSC, UK. |
| Uncontrolled Keywords: | sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 05 Mar 2025 10:30 |
| Last Modified: | 28 Mar 2025 13:14 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/98676 |
| DOI: | 10.1126/science.abq1841 |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |